PubMed:32755653
Annnotations
LitCovid-OGER-BB
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 33-38 | CHEBI:67079 | denotes | anti- |
| T2 | 33-38 | CHEBI:67079 | denotes | anti- |
| T3 | 79-87 | SP_7 | denotes | COVID-19 |
| T4 | 401-407 | UBERON:0007023 | denotes | adults |
| T5 | 446-454 | SP_7 | denotes | COVID-19 |
| T6 | 578-585 | GO:0007612 | denotes | learned |
| T7 | 730-735 | GO:0016265 | denotes | death |
| T8 | 870-880 | CL:0000542 | denotes | lymphocyte |
| T9 | 914-919 | CHEBI:67079 | denotes | anti- |
| T10 | 914-919 | CHEBI:67079 | denotes | anti- |
| T11 | 929-935 | CHEBI:67079 | denotes | agents |
| T12 | 929-935 | CHEBI:67079 | denotes | agents |
| T13 | 941-950 | CHEBI:31781 | denotes | lopinavir |
| T14 | 941-950 | CHEBI:31781 | denotes | lopinavir |
| T15 | 941-950 | DG_23 | denotes | lopinavir |
| T16 | 951-960 | DG_30 | denotes | ritonavir |
| T17 | 969-981 | CHEBI:2955 | denotes | azithromycin |
| T18 | 969-981 | CHEBI:2955 | denotes | azithromycin |
| T19 | 969-981 | DG_6 | denotes | azithromycin |
| T20 | 1017-1035 | CHEBI:5801 | denotes | hydroxychloroquine |
| T21 | 1017-1035 | CHEBI:5801 | denotes | hydroxychloroquine |
| T22 | 1017-1035 | DG_20 | denotes | hydroxychloroquine |
| T23 | 1218-1227 | UBERON:0002048 | denotes | Pulmonary |
| T24 | 1597-1608 | NCBITaxon:1 | denotes | individuals |
| T25 | 1610-1620 | CL:0000542 | denotes | lymphocyte |
| T26 | 1811-1820 | UBERON:0002048 | denotes | pulmonary |
| T27 | 1880-1901 | CHEBI:67079 | denotes | anti-infective agents |
| T28 | 1880-1901 | CHEBI:67079 | denotes | anti-infective agents |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 870-880 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
| T2 | 1610-1620 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 79-87 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T2 | 446-454 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 424-425 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T2 | 444-445 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T3 | 597-600 | http://purl.obolibrary.org/obo/PR_000001343 | denotes | Aim |
| T4 | 868-869 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T5 | 1045-1047 | http://purl.obolibrary.org/obo/CLO_0001407 | denotes | 52 |
| T6 | 1081-1082 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T7 | 1451-1452 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T8 | 1687-1688 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T9 | 1788-1789 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T10 | 1853-1854 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 33-54 | Chemical | denotes | anti-infective agents | http://purl.obolibrary.org/obo/CHEBI_35441 |
| T2 | 147-168 | Chemical | denotes | anti-infective agents | http://purl.obolibrary.org/obo/CHEBI_35441 |
| T3 | 426-434 | Chemical | denotes | medicine | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T4 | 914-935 | Chemical | denotes | anti-infective agents | http://purl.obolibrary.org/obo/CHEBI_35441 |
| T5 | 941-960 | Chemical | denotes | lopinavir-ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T6 | 941-950 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T7 | 951-960 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T8 | 969-981 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
| T9 | 983-986 | Chemical | denotes | AZI | http://purl.obolibrary.org/obo/CHEBI_2955 |
| T10 | 999-1002 | Chemical | denotes | AZI | http://purl.obolibrary.org/obo/CHEBI_2955 |
| T11 | 1017-1035 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T12 | 1302-1308 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
| T13 | 1362-1365 | Chemical | denotes | AZI | http://purl.obolibrary.org/obo/CHEBI_2955 |
| T14 | 1508-1511 | Chemical | denotes | AZI | http://purl.obolibrary.org/obo/CHEBI_2955 |
| T15 | 1833-1839 | Chemical | denotes | oxygen | http://purl.obolibrary.org/obo/CHEBI_25805 |
| T16 | 1880-1901 | Chemical | denotes | anti-infective agents | http://purl.obolibrary.org/obo/CHEBI_35441 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-120 | Sentence | denotes | Impact of medical care including anti-infective agents use on the prognosis of COVID-19 hospitalized patients over time. |
| T2 | 121-134 | Sentence | denotes | INTRODUCTION: |
| T3 | 135-206 | Sentence | denotes | Interest of anti-infective agents in COVD-19 showed discrepant results. |
| T4 | 207-307 | Sentence | denotes | However, there is no evaluation about the impact in changes of practices on the prognosis over time. |
| T5 | 308-316 | Sentence | denotes | METHODS: |
| T6 | 317-455 | Sentence | denotes | Single center, retrospective study, conducted from March 5th to April 25th 2020, in adults hospitalized in a medicine ward for a COVID-19. |
| T7 | 456-596 | Sentence | denotes | Patient characteristics were compared between 2 periods (before/after March 19th) considering French guidelines issued by learned societies. |
| T8 | 597-736 | Sentence | denotes | Aim of the study was to evaluate how medical care impacted unfavorable outcome, namely admission in intensive care unit (ICU) and/or death. |
| T9 | 737-745 | Sentence | denotes | RESULTS: |
| T10 | 746-896 | Sentence | denotes | One hundred thirty-two patients were admitted, mean age was 59.0 ± 16.3 years, mean CRP level was 84.0±71.1 mg/L, 46% had a lymphocyte count<1000/mm3. |
| T11 | 897-1049 | Sentence | denotes | When prescribed, anti-infective agents were lopinavir-ritonavir (n=12), azithromycin (AZI) (n=28) and AZI combined with hydroxychloroquine (HCQ) (n=52). |
| T12 | 1050-1149 | Sentence | denotes | Between the 2 periods we noted a significant decrease of ICU admission, from 43% to 12% (p<0.0001). |
| T13 | 1150-1217 | Sentence | denotes | Delays until transfer in ICU were similar between periods (p=0.86). |
| T14 | 1218-1421 | Sentence | denotes | Pulmonary CT-scan were significantly more performed (from 50% to 90%, p<0.0001), as oxygen-dependency (53% vs 80%, p=0.001) and prescription of AZI±HCQ (from 25% to 76%, p<0.0001) were greater over time. |
| T15 | 1422-1647 | Sentence | denotes | Multivariate analyses showed a reduction of unfavorable outcome in patients receiving AZI±HCQ (HR=0.45, 95%IC [0.21-0.97], p=0.04), especially among an identified category of individuals (lymphocyte≥1000/mm3 or CRP≥100 mg/L). |
| T16 | 1648-1659 | Sentence | denotes | CONCLUSION: |
| T17 | 1660-1902 | Sentence | denotes | The present study revealed a significant decrease of admission in ICU over time probably related to multiple factors, including a better indication of pulmonary CT-scan, of oxygen therapy, and a suitable prescription of anti-infective agents. |